Figure S1. ELEANORS are prognostic for late recurrence of ER-positive breast cancer.

(A) Kaplan-Meier curves showing relapse-free survival (RFS) of ELEANOR+ and – in Luminal A-like (left) and B-like (right) breast cancer patients. (B) Kaplan-Meier curves showing relapse-free survival (RFS, top) and overall survival (OS, bottom) of patients with ELEANOR + and - in their primary tumors. The curves in Fig. 1E are divided into early (left, 0 to 5 or 8 years after surgery) and late (right, >5 or 8 years after surgery) time windows. ELEANOR+ patients exhibited poor prognoses only in the later time window (right) for both RFS (top) and OS (bottom). Log-rank statistics are based on all data up to 5 or 8 years, with administrative censoring at 5 or 8 years. P values were calculated by the log-rank test.

Log-rank statistics after 5 or 8 years after surgery are based on all patients who were recurrence-free and surviving at 5 or 8 years. (C) Kaplan-Meier curves for RFS in ER-positive breast cancer patients with a history of adjuvant endocrine therapy (n=122).